A robotic guidance and placement system, the IGAR system can be utilized inside of a magnetic resonance imaging (MRI) bore.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the IGAR system, a robotic guidance and placement system that is compatible with magnetic resonance imaging (MRI).
Insight Medbotics, the developer of the IGAR system, noted the robotics system is the first to gain FDA clearance for use inside of an MRI bore, and is cleared for breast biopsy indications.1
Preliminary research with IGAR biopsies resulted in lower pain scores at one week as well as reduced scarring at one week and one month in comparison to manual breast biopsies.2
“Our team has long believed in the untapped potential of accessible MRI imaging, artificial intelligence and robotics together to improve quality of life for patients,” noted Fazila Seker, the CEO of Insight Medbotics. “Many teams are researching viable paths to take robotics into the MRI suite, but IGAR is the first to secure FDA clearance. This regulatory achievement advances our long-term vision, and our commitment to delivering technology that supports the future of precision medicine.”
References
1. Insight Medbotics. Insight Medbotics announces world’s first FDA-cleared, MRI-compatible robot. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/insight-medbotics-announces-worlds-first-fda-cleared-mri-compatible-robot-301925289.html . Published September 13, 2023. Accessed September 13, 2023.
2. Anvari M, Chapman T, Barlow K, Cookson T, Van Toen C, Fielding T. Clinical safety and efficacy of a fully automated robot for magnetic resonance imaging-guided breast biopsy. Int J Med Robot. 2023;19(2):e2472. doi: 10.1002/rcs.2472.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.